Larvol Delta - ArriVent-to-Present-Two-Preclinical-Posters-on-the-EGFR-Inhibitor-Firmonertinib-and-on-the-Novel-dualtarget-MUC16NaPi2b-Tetravalent-ADC-ARR002-at-the-2026-AACR-Annual-Meeting

Ivesa (firmonertinib) - Allist, ArriVent

ARR-002 - ArriVent

https://www.globenewswire.com/news-release/2026/03/17/3257720/0/en/ArriVent-to-Present-Two-Preclinical-Posters-on-the-EGFR-Inhibitor-Firmonertinib-and-on-the-Novel-dual-target-MUC16-NaPi2b-Tetravalent-ADC-ARR-002-at-the-2026-AACR-Annual-Meeting.html

Mar 17, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next